
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is a Buy-rated ophthalmic pharmaceutical and medical technology company with significant growth potential, backed by its iDose TR sustained-release drug delivery implant and its positive Epioxa survey checks. Despite potential headwinds from the proposed LCD requirements, the company's strong portfolio of products for glaucoma and corneal disorders, along with its innovative pipeline, make it a promising investment opportunity. With double-digit revenue growth expected and a price target of $150 based on an EV/sales multiple of 10.5x 2027E revenue, Glaukos is poised for success in the ophthalmic market.
Bears say
Glaukos is facing multiple headwinds that could negatively impact their revenues and stock performance. These include potential LCD restrictions for their iDose TR implant, which is their main source of revenue, the competitive and crowded MIGS market, potential reimbursement challenges, and slow adoption of their new medication, Epioxa. The proposed LCD restrictions may limit their market reach and slow down their growth, while the competitive landscape and reimbursement challenges could affect their existing products. Additionally, slow adoption of Epioxa could result in lower revenues and hinder their plans for growth. These factors could lead to a decline in their stock price and may make them a risky investment option.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares